ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2016
At a glance
- Drugs Veliparib (Primary) ; Mitomycin
- Indications Solid tumours
- Focus Adverse reactions
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 09 Feb 2016 Results published in the Journal of the National Cancer Institute
- 13 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 May 2016 as reported byClinicalTrials.gov record.